Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
Published version of a preprint
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Targeted therapy against the BRAF/mitogen-activated protein kinase (MAPK) pathway is a promising new therapeutic approach for the treatment of melanoma. Treatment with selective BRAF inhibitors results in a high initial response rate but limited duration of response. To counter this, investigators propose combining this therapy with other targeted agents, addressing the issue of redundancy and signaling through different oncogenic pathways. An alternative approach is combining BRAF/MAPK-targeted agents with immunotherapy. Preliminary evidence suggests that oncogenic BRAF (BRAFV600E) contributes to immune escape and that blocking its activity via MAPK pathway inhibition leads to increased expression of melanocyte differentiation antigens (MDA). Recognition of MDAs is a critical component of the immunologic response to melanoma, and several forms of immunotherapy capitalize on this recognition. Among the various approaches to inhibiting BRAF/MAPK, broad MAPK pathway inhibition may have deleterious effects on T lymphocyte function. Here, we corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAFV600E in melanoma cell lines and tumor digests results in increased levels of MDAs, which is associated with improved recognition by antigen-specific T lymphocytes. However, treatment with MEK inhibitors impairs T lymphocyte function, whereas T-cell function is preserved after treatment with a specific inhibitor of BRAFV600E. These findings suggest that immune evasion of melanomas mediated by oncogenic BRAF may be reversed by targeted BRAF inhibition without compromising T-cell function. These findings have important implications for combined kinase-targeted therapy plus immunotherapy for melanoma. Cancer Res; 70(13); 5213–9. ©2010 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a deleterious effect of MEK inhibition on T lymphocyte proliferation and antigen-specific T lymphocyte activation has been observed in melanoma [238,239].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [239]
In the citing paper
“This may partly explain why CRC patients do not benefit from MEK inhibitors and immune checkpoint inhibitors.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [239]
In the citing paper
“both BRAF and MEK inhibitors (including the FDA-approved agents vemurafenib, dabrafenib, and trametinib) mediate various cancer-cell-dependent immunostimulatory effects”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Boni et al., 2010
In the citing paper
“upregulation of TAAs (Boni et al., 2010; Frederick et al., 2013)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Boni et al., 2010
In the citing paper
“this reflects the key role of MEK signaling in the expansion of naive T cells at priming, as well as in the protection of tumor-infiltrating CD8 + CTLs from the lethal consequences of chronic TCR stimulation (Boni et al., 2010; Ebert et al., 2016)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Boni et al., 2010
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602 · cited 1×
“The overall survival for patients with metastatic melanoma is poor (1, 2), and novel forms of treatment are needed.”
BackgroundSelf-citationAdoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659 · cited 1×
“one of the most successful forms of immunotherapy incorporates adoptive transfer of autologous T lymphocytes after a lymphodepleting preconditioning regimen (10).”
BackgroundJohnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418 · cited 2×
“PBLs were obtained from melanoma patients on protocol and stimulated in vitro and transduced with TCR-encoding retroviral vectors as previously described (12).”
BackgroundMethodSelf-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 735
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., Hatton, C., Chopra, R., Oberholzer, P. A., Karpova, M. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905833106 · Cited by 633 · cited 1×
“Functional redundancy and compensatory activity through alternate signaling pathways might explain the low response rates to MEK inhibitors and the emergence of resistance seen in patients treated with selective BRAF inhibitors (7, 8).”
BackgroundOncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T., & Marais, R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002734 · Cited by 278
Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9000 · Cited by 229 · cited 2×
“Preliminary results of a phase I/II trial with a selective BRAF inhibitor suggest that objective responses are seen in the majority of patients whose tumors harbor BRAF (6).”
BackgroundSelf-citation
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“…(Chapman et al., 2011; Hauschild et al., 2012), it is associated with favorable effects in the tumor microenvironment, including increased antigen (Boni et al., 2010) and HLA expression (Bradley et al., 2015), increased T cell infiltrate, reduced immunosuppressive cytokines (Frederick et al.,…”
Self-citationInfluence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
“Güz Sayısı 2012 | Cilt:5 | Sayı:6 İmmünoloji Çalışma Grubu 2012 uygulanması melanomada tümörle birleşmiş antijenlerin upregülasyonuna öncülük edip bu sayede T hücrelerinin tümörü tanımasını sağladığı gösterilmiştir (162).”
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
“In this context, an unexpected link between BRAF inhibitors and the expression of melanoma T cell antigens was recently uncovere”
BackgroundTumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Metadata
- Authors
- Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., Tsao, H., & Wargo, J. A.
- Affiliations
- Harvard University (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2010-06-30
- Volume
- 70
- Issue
- 13
- Pages
- 5213-5219
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2116376943
- Cited by
- 742
- References
- 21
- Citations by year
- 2026: 15 · 2025: 13 · 2024: 14 · 2023: 50 · 2022: 41 · 2021: 40 · 2020: 53 · 2019: 40 · 2018: 39 · 2017: 60 · 2016: 49 · 2015: 60 · 2014: 73 · 2013: 95 · 2012: 51
- FWCI
- 25.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Massachusetts General Hospital
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR043369)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- BRAF V600E mutation, melanoma, MAPK inhibition, MEK inhibitors, melanocyte differentiation antigens, T cell recognition, immune evasion, T lymphocyte function, targeted therapy, immunotherapy, combination therapy
- MeSH terms
- Antigens, Neoplasm, Benzamides, Butadienes, Combined Modality Therapy, Diphenylamine, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Proteins, Nitriles, Oxidoreductases, T-Lymphocytes, Epitopes, T-Lymphocyte, Intramolecular Oxidoreductases, MAP Kinase Signaling System, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, gp100 Melanoma Antigen, MART-1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-0118
- The paper
- Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., Tsao, H., & Wargo, J. A. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-0118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.